Business
Notification of transaction
Notification of transaction.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n Hikma Pharmaceuticals Plc\n21 January 2008\n\n\n Notification of transaction by Directors\n\nLONDON, 21 January 2008 - Hikma Pharmaceuticals PLC (the 'Company') (LSE: HIK)\n(DIFX:HIK) announces that the Directors of the Company listed below, and Darhold\nLimited, being a connected person for the purposes of the Listing Rules,\nnotified the Company on 17 January 2008, that they had undertaken the following\nsubscriptions of shares as part of the of the placing undertaken by the Company\non that date:\n\n\nName Shares Percentage of enlarged issued share Price\n subscribed capital\nDarhold 5,233,056 2.783 480 pence\nLimited\nSamih Darwazah 168,944 0.09 480 pence\nSaid Darwazah 60,665 0.032 480 pence\nMazen Darwazah 55,633 0.03 480 pence\n\n\nFollowing the notification, each of the Directors and Darhold Limited have the\nfollowing holdings of ordinary shares of 10 pence each in the capital of the\nCompany representing the percentages of the enlarged issued ordinary share\ncapital of the Company set out below.\n\nName No. Of Ordinary Percentage of enlarged issued \n Shares share capital\nDarhold 57,883,028 30.783\nLimited\nSamih Darwazah 1,875,450 0.997\nSaid Darwazah 673,445 0.358\nMazen Darwazah 617,591 0.328\n\nEach of the above individuals is both a director and a Person Discharging\nManagerial Responsibility in respect of the Company. Darhold Limited is\nconnected with the above directors for the purposes of the Listing Rules. The\nabove notification relates to DTR 3.1.4R(1)(a) and other Listing Rules.\n\n\n -- ENDS --\n\n\n\nEnquiries:\n\nHikma Pharmaceuticals PLC\nHenry Knowles +44 20 7399 2760\nCompany Secretary\nSusan Ringdal +44 20 7399 2760\nInvestor Relations Director\n\nBrunswick Group\nJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959\n\n\nAbout Hikma\n\nHikma Pharmaceuticals PLC is a fast growing multinational group focused on\ndeveloping, manufacturing and marketing a broad range of both branded and\nnon-branded generic and in-licensed pharmaceutical products. Hikma's operations\nare conducted through three businesses: 'Branded', 'Injectables' and 'Generics'.\nHikma's operations are based principally in the Middle East and North Africa\n('MENA') region, where it is a market leader and sells across 17 countries, the\nUnited States and Europe. In 2006, the Group achieved revenues of $317 million\n(2005 $262 m...